
TTRX Stock Forecast & Price Target
TTRX Analyst Ratings
Bulls say
Turn Therapeutics is a clinical-stage biotechnology company that has developed a proprietary platform technology called PermaFusion designed to enhance drug performance for the treatment of inflammatory skin diseases. Their lead product, GX-03, is being studied for moderate-to-severe eczema and has shown promising results in preclinical and real-world studies. With a strong focus on expanding their platform into other dermatological indications, coupled with a newly announced loan agreement that provides much-needed capital, Turn Therapeutics is poised for growth and success in the future.
Bears say
Turn Therapeutics is heavily reliant on its proprietary PermaFusion platform technology and its lead program, GX-03, which is currently being evaluated in a clinical study for moderate-to-severe eczema. While the company has secured a potential source of funding through a capital commitment, it is not guaranteed and comes with potential future dilution. Additionally, the lack of transparency in the company's patent portfolio makes it difficult to fully assess the strength of its intellectual property and potential for competitors to develop similar solutions.
This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares